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Abstract
The Ataxia Telangiectasia Mutated (ATM) gene is frequently inactivated 
in lymphoid malignancies such as and Mantle Cell Lymphoma (MCL) and is 
associated with defective apoptosis, especially in response to standard cytotoxic 
chemotherapy. ATM deficient cells exhibit impaired homologous recombination 
and the inability to correct double strand DNA breaks. Inhibition of poly (ADP-
ribose) Polymerase (PARP), which is required for DNA double strand break 
repair, has been shown to sensitize ATM-deficient tumor cells to killing. We 
investigated in vitro and in vivo sensitivity to the PARP inhibitor olaparib in the 
ATM deficient mantle cell lymphoma cell line Granta-519. Olaparib monotherapy 
and in combination with cisplatin or bendamustine confirmed decreased 
proliferation in vitro. A Nonobese Diabetic/Severe Combined Immunodeficient 
(NOD/SCID) murine xenograft model with the Granta-519 cell line did not result 
in a significantly reduced tumor load following treatment with olaparib in vivo.
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Introduction
Cancer is a disease of genomic instability and can arise through 
aberrant DNA double strand breaks leading to the formation of 
chromosomal translocations, deletions, and inversions. These genomic 
aberrations occur at an increased frequency in cells with inherited 
or somatically acquired mutations that results in compromised 
DNA repair mechanisms. Hereditary mutations of genes involved in 
homologous recombination, such as Ataxia Telangiectasia (ATM), 
Breast Cancer (BRCA) [1,2], and TP53 can result in an increased risk 
of cancer development. 
ATM is a serine/threonine protein kinase that initiates cell cycle 
checkpoint signaling in response to DNA damage secondary to 
radiation or alkylator based therapy [3-5]. Deficiency of ATM exhibits 
radio sensitivity, loss of cell cycle checkpoints, and p53. Following 
DNA damage, cells with ATM deficiency displays prolonged DNA 
Double Strand Breaks (DSB) and retention of DNA proteins at the 
site of these breaks as intra-nuclear foci [4-8]. Similar to BRCA loss 
of function genes, ATM loss or deficiency leads to cancer cells relying 
on single strand DNA repair mechanisms from Poly (ADP-ribose) 
polymerase-1 (PARP-1).
Synthetic lethality using PARP inhibitors has emerged as a 
new potential therapeutic strategy to exploit tumor‐specific genetic 
alterations. Synthetic lethality is defined as the premise, whereby, 
deletion of one of two genes independently has no effect on cellular 
viability, whereas, simultaneous loss of both genes is lethal. The utility 
of this approach was first demonstrated when cells with mutations in 
the breast and ovarian susceptibility genes BRCA1 and BRCA2 were 
shown to be extremely sensitive to small molecule inhibitors of the 
DNA Single Strand Break (SSB) sensing protein PARP‐1.
Deficiency of ATM occurs in 20-50% of Mantle Cell Lymphoma 
(MCL) cases and has the largest incidence of any non-Hodgkin’s 
subtype [9,10]. MCL is a B-cell non-Hodgkin lymphoma 
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characterized by the genetic hallmark of a chromosomal translocation 
t(11;14) resulting in aberrant cyclin D1 expression [11]. In vitro data 
evaluating monotherapy of the PARP-inhibitor olaparib in ATM-
deficient B-cell chronic lymphocytic leukemia induced significant 
killing through mitotic catastrophe independent of apoptosis [7]. 
Additionally, in lymphoid cell lines Granta-519 and UPN2, which 
have low levels of ATM, olaparib decreased tumor growth [3]. In 
this study we investigated the PARP inhibitor olaparib with standard 
chemotherapy used to treat MCL ATM deficient lymphoid tumors.
Methods
Cell proliferation assay
Suspensions of the lymphoid Granta-519 cells which were provided 
by Drs. Chen and Plunkett at MD Anderson Cancer Center were 
exposed to increasing concentrations of olaparib (Selleck Chemicals, 
Houston, TX) and chemotherapy (cisplatin; bendamustine) for up to 
72 hours. Tumor growth potential was established using the Cell Titer 
96 cytotoxicity assay (Promega, Madison, WI). An amount of 40μl 
of the tetrazolium dye was added to each well of the plate and then 
incubated for an additional 4 hours. Optical Density (OD) was read 
directly at 492nm using the automated Dynex plate reader.
Western Blotting
Protein was loaded and run on Any kD Mini-PROTEAN TGX 
precast-polyacrylamide gel, transferred to nitrocellulose membranes 
(Bio-Rad Laboratories®), and blocked. Membranes were developed 
following exposure to the following antibodies: Annexin V (Santa 
Cruz Biotechnology Inc.); mouse anti-CHEK1,mouse anti-CHEK2, 
rabbit anti-cleaved caspase 7, rabbit anti-cleaved caspase 3, and 
rabbit anti-GAPDH (Cell Signaling Technology, City St); rabbit 
anti-cleaved PARP(Asp214), rabbit anti-PARP antibody, mouse 
anti-Phospho-p53(Ser15) and mouse anti-p53 antibody from Cell 
Signaling Technology; rabbit anti-Bax antibody 50 and rabbit anti-
Bax antibody 100 from Biolegend.
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Murine xenograft model
The lymphoid cell line Granta-519 was mixed with Matrigel 
(BD Bioscience) and injected subcutaneously (200μl containing 
10×106 Granta-519) into the right flanks of 6-8 week-old 
immunocompromised NOD/SCID mice. Tumor growth was 
monitored twice weekly by measurement of the long and short 
diameters of the tumor using calipers. Caliper measurement of the 
longest perpendicular tumor diameter was performed to estimate 
the tumor volume, using the following formula: 4π/3×(tumor 
width/2)2×(tumor length/2), representing the three-dimensional 
volume of an ellipse. When the tumor volume reached approximately 
100-200 mm3, mice were randomly assigned into treated groups. 
The maximum volume observed was 2656mm3. Body weight 
endpoints were not collected. Treatment groups included: vehicle 
control (n=6), olaparib starting on day 7 of implant at 50mg/kg/day 
Monday through Friday, no more than 28 days of treatment (n=6), 
bendamustine 10mg/kg on day 7 and day 14 (n=6); olaparib 50mg/
kg/day Monday through Friday, no more than 28 days of treatment 
plus bendamustine 10mg/kg on day 7 and 14 (n=6). Drugs and 
control vehicle were be administered by gavage feeding (olaparib) 
or intraperitoneal injection (bendamustine). Mice were sacrificed 
at 8 weeks after drug treatment or when they become moribund (if 
earlier). 
All studies were carried out in accordance with, and approval 
of, the Institutional Animal Care and Use Committee of Indiana 
University School of Medicine, and the Guide for the Care and Use 
of Laboratory Animals (IACUC study #10416). NOD/scid mice 
were obtained from the in vivo Therapeutics Core of the Indiana 
University Simon Cancer Center. Animals were maintained under 
pathogen-free conditions and maintained on Teklad Lab Animal 
Diet (TD 2014, Harlan Laboratories USA) with ad libitum access 
to sterile tap water under a 12-hour light-dark cycle at 22-24°C. All 
techniques are established such that experiments are conducted 
in the most efficient manner and using the minimum number of 
animals. Mice monitoring occurred daily for determine of weight and 
general appearance. Mice were euthanized immediately if any of the 
following are evident: Failure to eat and drink for >48 hours; rapid 
loss of 15-20% body weight; inactivity with hunched posture; lesions 
that interfere with ability to eat and drink; evidence of self-mutilation, 
lesions with major ulcerating surfaces; loss of righting reflex and 
inability to maintain upright posture; loss of general body condition 
with spine becoming visible; dehiscence of wounds and/or evidence 
of infection not responsive to veterinary treatment. Euthanasia 
occurred with CO2 inhalation followed by cervical dislocation as a 
secondary method.
In vivo Bioluminescent Imaging (BLI)
In vivo Imaging: In vivo imaging was performed as described 
by Shannon et al, with some minor modifications [12]. Briefly, post 
tumor implantation and continuing weekly thereafter, dynamic 
bioluminescence images were acquired on a Berthold NightOwl 
(Berthold Inc. USA) at 40˚C, where up to 3 mice per session were 
simultaneously scanned. In denuded mice, anesthetic induction 
was achieved with 2-4% isoflurane, and animals were administered 
150mg/kg D-luciferin (Caliper Lifescience USA) subcutaneously. 
Mice were sequentially imaged at 2 min intervals for 40 mins with 
image integration times ranging from 1 to 120 sec/image. At the 
completion of the sequence, anatomical reference photos were also 
acquired to generate fused image sets.
Image analysis: To provide visualization, segmentation and 
time series quantification from the 40 min scan, BLI and anatomical 
reference images were imported into custom developed software 
(eLumenate, developed by Dr. Territo). Pseudo-colored parametric 
overlays of BLI time-series with anatomical reference images were 
dynamically constructed for each animal. Using the image of the time 
series with the peak light emission for each individual animal, ROIs 
were designated for both primary tumors and a metastatic region. 
Primary tumors were segmented through time using the semi-
Figure 1: Cytotoxic Results in ATM deficient Granta-519 Mantle cell lines.
Proliferation of Granta519 mantel cell lymphoma cell lines following exposure to bendamustine, cisplatin, and olaparib at increasing cytotoxic concentrations.  In 
combination: bendamstine 254µM plus olaparib 0.15mM, cisplatin 1µg plus olaparib 0.15mM and monotherapy of olaparib 0.15mM, cisplatin 1µg, and bendamustine 
254µM. Analyzed with ANOVA and Dunnett’s multiple comparisons test: *p=0.0163, **p=0.0272, #p=0.0063, ^p=0.0221, βp= 0.0046, χp=0.0022, εp=0.0064, 
δp=0.0018, ϕp=0.0059.
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automated maximum entropy ROI algorithm [13]. The extracted 
time series were then analyzed for average emission flux density in a 
region and the integral of emission flux according to:
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Where, IA, IP, i, n, m, a, b, x, AUC and t are the average emission 
flux density (Ph/s*mm2), pixel emission flux density, pixel, subject, 
total number of pixels, integration start, integration end, integration 
interval, area under the curve (Ph/mm2), and time points, respectively. 
To minimize the role of tumor and animal motion on time course 
parameters, individual ROIs across image frames were aligned 
by computing the per frame center of gravity [14] offset between 
successive frames, and applying the x-y offset to the ROI prior to 
computing IP or IA described in equations 1 or 2, respectively.
Statistical analysis
In vitro Data are presented as means +/- SD and analyzed 
using ANOVA followed by Dunnett’s test of multiple comparison. 
Statistical difference in tumor volume were determined using the 
Student’s t test. GraphPad Prism 7 software (GraphPad Software, 
Inc., La Jolla, CA, USA) was used to perform all statistical analysis, 
using Student’s t test or nonparametric Mann-Whitney test/ANOVA 
for comparisons between groups of samples.
Results
ATM deficient lymphoid tumor cell sensitivity to PARP 
inhibition and cytotoxic therapy
To assess the ability of PARP inhibition to increase the effect 
of standard mantle cell lyphoma therapy, we tested the ability of 
olaparib to sensitize ATM mutant Granta-519 cells to cisplatin and 
bendamustine (Figure 1). The percent proliferation of lymphoid 
cells was at 24, 48, and 72 hours with olaparib 0.15mM monotherapy 
was 63.9%, 12.9%, and 6.56%, respectively. However, the addition of 
olaparib to cisplatin or bendamustine provide a similar rate of efficacy 
against Granta-519 proliferation.
Apoptosis, caspase, and downstream activity (western 
blots results)
To assess the effects of olaprib and bendamustine on downstream 
molecules, we used Western blot analysis (Figure 2) to observed 
p53, phosphorylated 52, caspase, cleaved PARP, and ANNEXIN. 
Inhibition of PARP-1 leads to the accumulation of DNA single-
strand breaks that are converted to DSBs during DNA replication 
[1,2,8]. In cells with defects in DSBs, CHEK pathways may be relied 
upon for single-strand repair. To assess this we evaluated CHEK1 and 
CHEK2 accumulation. Bax was analyzed as it has been observed to be 
increased with bendamustine initiated apoptosis [15].
The results indicated that the bendamustine and olaparib 
combination resulted in an increase in cleaved PARP, cleaved caspase 
7, and phopho-53. No difference was observed in CHEK1 or CHEK2.
Effect of olaparib with or without cisplatin or bendamustine 
in a Granta-519 Xenograph model
To investigate the in vivo impact of olaparib, we generated murine 
xenograft models of the ATM deficient cell line, Granta-519 cell at 
a volume of 100cells/mm3 injected subcutaneously into the right 
flanks. Tumors were assessed via caliper and bioluminescent imaging 
(Figure 3). Following inoculation mice were treated with vehicle 
control, olaparib, bendamustine, or olaparib plus bendamustine. 
Figure 2: Treatment with olaparib in ATM deficient Granta-519 sensitized to cytotoxic chemotherapy.
Western blot analysis of Granta-519 cells showing increased cleavage of PARP1, caspase 7, cleaved caspase-7, and phospho-53 after olaparib montherapy or in 
combination with bendamustine. Granta-519 cells treated with bendamustine 127µM and or olaparib 7.5mM for 24 hours.
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One mouse death was likely dosing related while the rest were alive 
at 34 days post lymphoma implantation. Combination therapy with 
bendamustine and olaparib produced a modest lag in lymphoma 
growth. Mean tumor volume on day 34 of caliper measurement was 
1732.1cells/mm3 +/- 1029.2cells/mm3 for the control vs. 1317.6cells/
mm3 +/- 399cells/mm3 (p=0.421) for the olaparib plus bendamustine 
combination (Figure 3).
Discussion
ATM deficiency in mantle cell lymphomas pose an interesting 
target in the era of precision medicine. The synthetic lethality 
approach is a novel therapeutic intervention, which has been validated 
clinically in ovarian cancers with regards to BRCA mutations [16]. 
Evaluation of BRCA mutation in the role of malignancy has led to 
the approval of olaparib, rucaparib, and niraparib in ovarian cancer, 
as well as, olaparib in BRCA mutated breast cancer. The Phase III 
OlympiAD trial in breat cancer showed a reduced risk of disease 
progression or death by 42% with olaparib compare to physicians 
choice chemotherapy [21]. Previous in vitro data suggested by 
Weston et al, provides efficacy data with olaparib as monotherapy in 
ATM deficient chronic leukemia cell lines [8].
In this current study, we demonstrated that the PARP inhibitor 
olaparib is able to enhance a pre-existing DNA repair defect in an 
ATM deficient mantle cell lymphoma cell line, Grant-519. The growth 
of ATM deficient Granta-519 tumor cells in a NOD/SCID xenograph 
model was not significantly decreased by olaparib monotherapy 
or combination therapy. Tumor volumes were assess by caliper 
measurements and via bioluminescent quantification. While a 
more pronounced benefit was observed with caliper measurement, 
bioluminescent imaging demonstrates the ability to detect microscopic 
tumors and provide a more accurate assessment of estimated tumor 
volumes in vivo [17]. In this study further evaluation with BLI did not 
support a significant decrease in Grant-519 growth with olaparib as 
monotherapy or in combination with bendamustine with regards to 
the in vivo model. Others studies have suggested that ATM deficient 
lymphomas with concomitant p53 and ATR mutations may allow for 
Figure 3: Tumor distribution pattern of one representative animal per 
treatment during days 5, 12, 20, and 32. In all cases, data are shown as 
peak emission photon density (Ph/s.mm2) and are scaled uniformly across 
subject and time.
greater sensitivity to olaparib [18,19]. Evaluating several mutations 
that may affect the lymphoma’s response to treatment is a next logical 
step in assessing synthetic lethality based therapy and may include 
a myriad of interdependent pathways such as the following: p53, 
ATR, CHEK1, CHEK2, loss of heterozygosity and levels of PARP 
expression [18-21].
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